|
|
|
|
| Mikart’s 50 years of experience as a CDMO in oral solid and nonsterile oral liquid dosage forms, combined with our specialization in pediatric, geriatric, and controlled-substance products, make us an ideal partner from formulation development through commercialization. We prioritize long-lasting relationships and a personalized, hands-on approach — delivering the reliability, technical expertise, and flexibility needed to meet your goals, navigate complexity, and consistently exceed expectations at every stage. |
|
|
|
|
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma | Chief Editor Louis Garguilo says like many readers, he agrees with the "wise and narrow decision" by the U.S. Supreme Court that President Trump cannot use the International Emergency Economic Powers Act to impose sweeping tariffs. At the same time, for those who immediately threw up an instant “Hooray!” he suggests checking yourself on why such enthusiasm. His analysis on what is actually best for our global outsourcing industry. | |
|
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
| A CDMO's Take On Psychedelic Formulation | Article | Upperton Pharma Solutions | Psychedelics show therapeutic promise, but face major formulation and regulatory hurdles. Advances in delivery and neuroscience may unlock new mental‑health treatments. |
|
|
| Focus On Your Core Business Strategy | Case Study | Eurofins PSS Insourcing Solutions | Learn how a large manufacturing client helped to focus on their core business with a solution that transitioned approximately 60% of the workforce and capitalized on the initial training investment. |
|
|
| Technology Selection To Enhance Bioavailability | Application Note | By Dr. David K. Lyon, Ph.D., Lonza | Bioavailability challenges are among the toughest problems faced by today’s formulators. This paper gives an overview of obstacles to bioavailability and summarizes the technology selection process. |
|
|
| GMP Manufacturing Cycle Time Reduction | Case Study | CAI | Identifying process redundancies and enhancing visual management allows manufacturers to stabilize workflows. These data-driven improvements can decrease operational variability by nearly 50%. |
|
|
|
Small Molecule Exponential Discovery | X-Chem | Assimilate how a data‑driven discovery model combines DEL screening, computational insights, and medicinal chemistry to accelerate hit‑to‑lead decisions, reduce risk, and enable efficient progression. |
|
|
|
Solid Form Services | Lonza | We have defined work flows to assess and select solid forms in a cost and time efficient manner that meets the needs of each individual program. |
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecules share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
